Table 3.
Baseline and changes in oral antidiabetic, antihypertensive and dyslipidemia medication according to basal albuminuria category
| Medication by baseline UACR | Baseline, n (%) | 24 months, n (%) |
|---|---|---|
| SGLT2i (mg/g) >300 30–300 <30 |
52 (42.6)
13 (54.2) 26 (39.4) 13 (40.6) |
56 (45.9)
14 (58.3) 29 (43.9) 13 (40.6) |
| Metformin (mg/g) >300 30–300 <30 |
61 (50)
10 (41.7) 37 (56.1) 14 (43.8) |
44 (36.1)
7 (29.2) 31 (47) 6 (18.8) |
| DPP4i (mg/g) >300 30–300 <30 |
19 (15.6)
1 (4.2) 11 (16.7) 7 (21.9) |
0 |
| Pioglitazone (mg/g) >300 30–300 <30 |
1 (0.8)
0 0 1 (3.1) |
2 (1.7)
1 (4.2) 0 1 (3.1) |
| anti-HTA (mg/g) >300 30–300 <30 |
120 (98.4)
23 (95.8) 65 (98.5) 32 (100) |
117 (95.9)
23 (95.8) 65 (98.5) 29 (90.6) |
| RASi (mg/g) >300 30–300 <30 |
117 (95.9)
23 (95.8) 64 (97.5) 31 (98.5) |
116 (95.1)
23 (95.8) 64 (97.5) 30 (97.4) |
| Statinsa (mg/g) >300 30–300 <30 |
116 (95.1)
23 (95.8) 63 (95.5) 30 (93.8) |
120 (98.4)
24 (100) 65 (98.5) 31 (96.9) |
anti-HTA: antihipertensive medication (includes β-blockers, calcium channel blockers, α-blockers, mineralocorticoidnŁ agonists and diuretics); DPP4i, dipeptyldipeptidase-4 inhibitor; RASi: renin–angiotensin system inhibitor. aIncludes ezetimibe.